RBC Capital raised the firm’s price target on Seagen (SGEN) to $229 from $155 and keeps an Outperform rating on the shares following the proposed acquisition of the company by Pfizer (PFE) at $229 per share. Seagen is a "strategically fit" player to further bolster Pfizer’s oncology capabilities and expertise, the analyst tells investors in a research note. RBC also anticipates a relatively low likelihood of other bidders emerging while noting that the deal’s regulatory FTC risks are "limited or manageable", and the firm believes the acquisition will close in late-2023/early-2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- Seagen price target raised to $229 from $210 at Oppenheimer
- Seagen (NASDAQ:SGEN) Stock Gained 54% YTD. Can Its Momentum Continue?
- Seagen price target raised to $228 from $145 at Barclays
- Seagen downgraded to Market Perform from Outperform at JMP Securities
- Seagen downgraded to Market Perform from Outperform at BMO Capital